Clinical Trial Search

Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — 0.09; 0.06 percentage of HbA1c — p=0.783

Primary: Number of Participants With Genitourinary Acute Toxicity — 44; 15; 0; 0 Participants

Primary: Treatment Success - Event Rates in Each Group — 15; 24; 59; 48 percentage of participants

Primary: Change of Number of Falls From Baseline to 6 Months — 0.28; 0.40 falls — p=0.55

Primary: Successful Completion of LipiFlow Treatment With Activator LFD-2100 — 100 Percent of eyes

Primary: Cumulative Stress Index — 647; 676 mmHg x minutes

Primary: Hypoglycemia Safety: Number of Participants With Blood Glucose (BG)) Readings < 50 Milligrams/Deciliter (mg/dL)) — 19; 1 Participants

Primary: T-max — 360; 180 minutes

Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants

Primary: Proportion of Responders in Each Treatment Group — 88; 98; 87 Participants — p=0.434

Primary: Mean Change From Baseline in the Monthly Migraine Days During the 28-day Post Treatment Period Ending With Week 12 — -3.46; -6.27; -6.09 Days — p=< .0001

Primary: Amount of Supplemental Postoperative Narcotic Analgesia in Oral Morphine Equivalents (OME) — 19.8; 23.6; 20.7; 25.2 mg morphine equivalents

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…

Primary: Number of Participants in Phase 2 With Anesthesia Success — 38; 4; 2; 16 participants